SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3005766885> ?p ?o ?g. }

Showing items 1 to 100 of ±279 with 100 items per page.

W3005766885 endingPage "464" @default.
W3005766885 startingPage "454" @default.
W3005766885 abstract "Background Inflammatory bowel disease (IBD) places a significant burden on health-care systems because of its chronicity and need for expensive therapies and surgery. With increasing use of biological therapies, contemporary data on IBD health-care costs are important for those responsible for allocating resources in Europe. To our knowledge, no prospective long-term analysis of the health-care costs of patients with IBD in the era of biologicals has been done in Europe. We aimed to investigate cost profiles of a pan-European, community-based inception cohort during 5 years of follow-up. Methods The Epi-IBD cohort is a community-based, prospective inception cohort of unselected patients with IBD diagnosed in 2010 at centres in 20 European countries plus Israel. Incident patients who were diagnosed with IBD according to the Copenhagen Diagnostic Criteria between Jan 1, and Dec 31, 2010, and were aged 15 years or older the time of diagnosis were prospectively included. Data on clinical characteristics and direct costs (investigations and outpatient visits, blood tests, treatments, hospitalisations, and surgeries) were collected prospectively using electronic case-report forms. Patient-level costs incorporated procedures leading to the initial diagnosis of IBD and costs of IBD management during the 5-year follow-up period. Costs incurred by comorbidities and unrelated to IBD were excluded. We grouped direct costs into the following five categories: investigations (including outpatient visits and blood tests), conventional medical treatment, biological therapy, hospitalisation, and surgery. Findings The study population consisted of 1289 patients with IBD, with 1073 (83%) patients from western Europe and 216 (17%) from eastern Europe. 488 (38%) patients had Crohn's disease, 717 (56%) had ulcerative colitis, and 84 (6%) had IBD unclassified. The mean cost per patient-year during follow-up for patients with IBD was €2609 (SD 7389; median €446 [IQR 164–1849]). The mean cost per patient-year during follow-up was €3542 (8058; median €717 [214–3512]) for patients with Crohn's disease, €2088 (7058; median €408 [133–1161]) for patients with ulcerative colitis, and €1609 (5010; median €415 [92–1228]) for patients with IBD unclassified (p<0·0001). Costs were highest in the first year and then decreased significantly during follow-up. Hospitalisations and diagnostic procedures accounted for more than 50% of costs during the first year. However, in subsequent years there was a steady increase in expenditure on biologicals, which accounted for 73% of costs in Crohn's disease and 48% in ulcerative colitis, in year 5. The mean annual cost per patient-year for biologicals was €866 (SD 3056). The mean yearly costs of biological therapy were higher in patients with Crohn's disease (€1782 [SD 4370]) than in patients with ulcerative colitis (€286 [1427]) or IBD unclassified (€521 [2807]; p<0·0001). Interpretation Overall direct expenditure on health care decreased over a 5-year follow-up period. This period was characterised by increasing expenditure on biologicals and decreasing expenditure on conventional medical treatments, hospitalisations, and surgeries. In light of the expenditures associated with biological therapy, cost-effective treatment strategies are needed to reduce the economic burden of inflammatory bowel disease. Funding Kirsten og Freddy Johansens Fond and Nordsjællands Hospital Forskningsråd. Inflammatory bowel disease (IBD) places a significant burden on health-care systems because of its chronicity and need for expensive therapies and surgery. With increasing use of biological therapies, contemporary data on IBD health-care costs are important for those responsible for allocating resources in Europe. To our knowledge, no prospective long-term analysis of the health-care costs of patients with IBD in the era of biologicals has been done in Europe. We aimed to investigate cost profiles of a pan-European, community-based inception cohort during 5 years of follow-up. The Epi-IBD cohort is a community-based, prospective inception cohort of unselected patients with IBD diagnosed in 2010 at centres in 20 European countries plus Israel. Incident patients who were diagnosed with IBD according to the Copenhagen Diagnostic Criteria between Jan 1, and Dec 31, 2010, and were aged 15 years or older the time of diagnosis were prospectively included. Data on clinical characteristics and direct costs (investigations and outpatient visits, blood tests, treatments, hospitalisations, and surgeries) were collected prospectively using electronic case-report forms. Patient-level costs incorporated procedures leading to the initial diagnosis of IBD and costs of IBD management during the 5-year follow-up period. Costs incurred by comorbidities and unrelated to IBD were excluded. We grouped direct costs into the following five categories: investigations (including outpatient visits and blood tests), conventional medical treatment, biological therapy, hospitalisation, and surgery. The study population consisted of 1289 patients with IBD, with 1073 (83%) patients from western Europe and 216 (17%) from eastern Europe. 488 (38%) patients had Crohn's disease, 717 (56%) had ulcerative colitis, and 84 (6%) had IBD unclassified. The mean cost per patient-year during follow-up for patients with IBD was €2609 (SD 7389; median €446 [IQR 164–1849]). The mean cost per patient-year during follow-up was €3542 (8058; median €717 [214–3512]) for patients with Crohn's disease, €2088 (7058; median €408 [133–1161]) for patients with ulcerative colitis, and €1609 (5010; median €415 [92–1228]) for patients with IBD unclassified (p<0·0001). Costs were highest in the first year and then decreased significantly during follow-up. Hospitalisations and diagnostic procedures accounted for more than 50% of costs during the first year. However, in subsequent years there was a steady increase in expenditure on biologicals, which accounted for 73% of costs in Crohn's disease and 48% in ulcerative colitis, in year 5. The mean annual cost per patient-year for biologicals was €866 (SD 3056). The mean yearly costs of biological therapy were higher in patients with Crohn's disease (€1782 [SD 4370]) than in patients with ulcerative colitis (€286 [1427]) or IBD unclassified (€521 [2807]; p<0·0001). Overall direct expenditure on health care decreased over a 5-year follow-up period. This period was characterised by increasing expenditure on biologicals and decreasing expenditure on conventional medical treatments, hospitalisations, and surgeries. In light of the expenditures associated with biological therapy, cost-effective treatment strategies are needed to reduce the economic burden of inflammatory bowel disease." @default.
W3005766885 created "2020-02-24" @default.
W3005766885 creator A5001139735 @default.
W3005766885 creator A5001326123 @default.
W3005766885 creator A5002919479 @default.
W3005766885 creator A5003121815 @default.
W3005766885 creator A5005330357 @default.
W3005766885 creator A5005601386 @default.
W3005766885 creator A5005657771 @default.
W3005766885 creator A5005805886 @default.
W3005766885 creator A5006196103 @default.
W3005766885 creator A5007236898 @default.
W3005766885 creator A5008566468 @default.
W3005766885 creator A5008573277 @default.
W3005766885 creator A5008723044 @default.
W3005766885 creator A5009503028 @default.
W3005766885 creator A5013167694 @default.
W3005766885 creator A5013593261 @default.
W3005766885 creator A5014634729 @default.
W3005766885 creator A5014734619 @default.
W3005766885 creator A5015033532 @default.
W3005766885 creator A5015550447 @default.
W3005766885 creator A5015814998 @default.
W3005766885 creator A5016591972 @default.
W3005766885 creator A5017642140 @default.
W3005766885 creator A5017795689 @default.
W3005766885 creator A5018678523 @default.
W3005766885 creator A5019960092 @default.
W3005766885 creator A5020923863 @default.
W3005766885 creator A5021651980 @default.
W3005766885 creator A5022448896 @default.
W3005766885 creator A5023115575 @default.
W3005766885 creator A5030357288 @default.
W3005766885 creator A5030614108 @default.
W3005766885 creator A5031778278 @default.
W3005766885 creator A5032343404 @default.
W3005766885 creator A5033989831 @default.
W3005766885 creator A5034112151 @default.
W3005766885 creator A5034141472 @default.
W3005766885 creator A5034569547 @default.
W3005766885 creator A5034852890 @default.
W3005766885 creator A5035484022 @default.
W3005766885 creator A5036036179 @default.
W3005766885 creator A5037223170 @default.
W3005766885 creator A5037438187 @default.
W3005766885 creator A5037542727 @default.
W3005766885 creator A5041140796 @default.
W3005766885 creator A5042173620 @default.
W3005766885 creator A5043240020 @default.
W3005766885 creator A5043492761 @default.
W3005766885 creator A5044320360 @default.
W3005766885 creator A5044665524 @default.
W3005766885 creator A5044724667 @default.
W3005766885 creator A5044878932 @default.
W3005766885 creator A5046490863 @default.
W3005766885 creator A5049035451 @default.
W3005766885 creator A5049491345 @default.
W3005766885 creator A5049988663 @default.
W3005766885 creator A5050552963 @default.
W3005766885 creator A5050910391 @default.
W3005766885 creator A5052535018 @default.
W3005766885 creator A5055687169 @default.
W3005766885 creator A5056236347 @default.
W3005766885 creator A5056683017 @default.
W3005766885 creator A5061087463 @default.
W3005766885 creator A5061303817 @default.
W3005766885 creator A5061397027 @default.
W3005766885 creator A5062100286 @default.
W3005766885 creator A5063284741 @default.
W3005766885 creator A5064403505 @default.
W3005766885 creator A5064419298 @default.
W3005766885 creator A5065070139 @default.
W3005766885 creator A5066086405 @default.
W3005766885 creator A5067108118 @default.
W3005766885 creator A5068091489 @default.
W3005766885 creator A5068268866 @default.
W3005766885 creator A5068388301 @default.
W3005766885 creator A5068975639 @default.
W3005766885 creator A5070038178 @default.
W3005766885 creator A5070778090 @default.
W3005766885 creator A5074210541 @default.
W3005766885 creator A5076951585 @default.
W3005766885 creator A5079160619 @default.
W3005766885 creator A5079393738 @default.
W3005766885 creator A5079545747 @default.
W3005766885 creator A5081001449 @default.
W3005766885 creator A5082499535 @default.
W3005766885 creator A5084212600 @default.
W3005766885 creator A5086692946 @default.
W3005766885 creator A5087372337 @default.
W3005766885 creator A5089763005 @default.
W3005766885 creator A5067764025 @default.
W3005766885 date "2020-05-01" @default.
W3005766885 modified "2023-10-18" @default.
W3005766885 title "Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study" @default.
W3005766885 cites W1537955720 @default.
W3005766885 cites W1965693751 @default.
W3005766885 cites W1993862222 @default.